Epilepsy Trial, Recruiting NCT02639325 Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT02639325
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 8 years of age or older.
  • People who have a single brain tumor (either a new tumor or one that has come back) and have also experienced seizures linked to that tumor. The tumor can be identified by a scan rather than surgery. The seizures need to have started within three months of the tumor being spotted on a scan, or — if the timing is unclear — the type of seizure fits with where the tumor is located. Having had just one seizure in the past is enough to meet this requirement, and people whose seizures stopped after starting anti-seizure medication are still eligible.

Who may not be able to join:

  • People who, at the time of joining the trial, are unable to understand an explanation of the study procedures due to a level of cognitive impairment that removes their ability to give informed consent. Note: children may still be eligible if a parent or guardian is able to give consent on their behalf, and adults with mental health conditions or mild cognitive difficulties who are still able to consent are not excluded on this basis. (Confirm with trial site how consent capacity will be assessed.)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kareem A Zaghloul, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

Phone: (301) 496-2921

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
26 January 2016
Est. completion
1 July 2032

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

change in seizure frequency, as measured by the Engel scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov